My research is focused on infectious diseases research and experimental therapeutics, with emphasis on Mycobacterium tuberculosis and nontuberculous mycobacteria, namely M. avium complex (MAC), M. kansasii, and M. abscessus.

One of the goals of my laboratory is to design safe, effective and short-course treatment regimens. To this end, repurposing drugs for treatment of tuberculosis could be the fastest ways to develop new regimens. My lab uses pre-clinical hollow fiber system model to perform pharmacokinetic/pharmacodynamic studies first to optimize the drug dose as monotherapy followed by combination regimens and compare the efficacy against the current standard of care regimen. In addition, the lab extensively uses mathematical modeling and simulations, genomics and transcriptomics technologies to translate the laboratory findings to clinics i.e, “bench-to-bedside”.

Among the major findings of our research work are establishment of pharmacokinetic variability as major cause of drug resistance in tuberculosis as oppose to the treatment non-adherence, determination of drug concentration threshold to predict treatment failure, first-in-man with live BCG instillation to study the immune response and vaccine development, first oral treatment regimen for children with drug resistant tuberculosis, new treatment regimens for MAC and M. kansasii, and discovery/repurposing of drugs that were previously thought to have no effect against these pathogen.

At UTHSCT, we are always open to new collaborations.